These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27534197)

  • 1. [A brand new stent technology: bioresorbable scaffolds].
    Muramatsu T; Ozaki Y
    Nihon Rinsho; 2016 Jun; 74 Suppl 4 Pt 1():365-71. PubMed ID: 27534197
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresorbable vascular scaffolds: the shape of things to come?
    Safian RD
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):472-3. PubMed ID: 22431381
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable scaffolds: the fee comes now and the reward comes later.
    Jabbour RJ; Colombo A
    Future Cardiol; 2016 Jul; 12(4):397-400. PubMed ID: 27291396
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-correction property a novel feature of bioresorbable coronary scaffolds.
    Diletti R; Ligthart JM; Ramdhan R; Van Mieghem NM
    Int J Cardiol; 2016 Jul; 214():417-8. PubMed ID: 27088402
    [No Abstract]   [Full Text] [Related]  

  • 7. What about the risk of thrombosis with bioresorbable scaffolds?
    Capodanno D; Joner M; Zimarino M
    EuroIntervention; 2015; 11 Suppl V():V181-4. PubMed ID: 25983162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioresorbable scaffolding after drug-coated balloons: a new chapter of the "leave nothing behind" saga.
    Cortese B; Sebik R; Seregni R; Silva PL
    Int J Cardiol; 2014 May; 173(3):e67-9. PubMed ID: 24704408
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

  • 10. Decade of histological follow-up for a fully biodegradable poly-L-lactic acid coronary stent (Igaki-Tamai stent) in humans: are bioresorbable scaffolds the answer?
    Nishio S; Takeda S; Kosuga K; Okada M; Kyo E; Tsuji T; Takeuchi E; Terashima T; Inuzuka Y; Hata T; Takeuchi Y; Harita T; Seki J; Ikeguchi S
    Circulation; 2014 Jan; 129(4):534-5. PubMed ID: 24470476
    [No Abstract]   [Full Text] [Related]  

  • 11. What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?
    Yamaji K; Räber L; Windecker S
    EuroIntervention; 2017 Feb; 12(14):1684-1687. PubMed ID: 28119252
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioresorbable vascular scaffolds: the promise of transience.
    Somaratne JB; Whitbourn RJ
    Intern Med J; 2013 Jun; 43(6):615-8. PubMed ID: 23745992
    [No Abstract]   [Full Text] [Related]  

  • 13. The future of BRS in bifurcations.
    Kraak RP; Grundeken MJ; Onuma Y; Tu S; Wykrzykowska JJ; Chevalier B; Ormiston J; Serruys PW
    EuroIntervention; 2015; 11 Suppl V():V188-92. PubMed ID: 25983164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a need for dedicated devices?
    Wykrzykowska JJ; Grundeken MJ; Stankovic G; Di Mario C
    EuroIntervention; 2015; 11 Suppl V():V139-42. PubMed ID: 25983149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques--insights from optical coherence tomography.
    Attizzani GF; Ohno Y; Capranzano P; La Manna A; Francaviglia B; Grasso C; Sgroi C; Tamburino C; Longo G; Fujino Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Dec; 170(2):e33-5. PubMed ID: 24210418
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical outcomes following bioresorbable scaffold implantation in small vessels.
    Tanaka A; Ruparelia N; Kawamoto H; Sticchi A; Sato K; Miyazaki T; Naganuma T; Chieffo A; Carlino M; Montorfano M; Latib A; Colombo A
    Int J Cardiol; 2016 Mar; 207():59-61. PubMed ID: 26797331
    [No Abstract]   [Full Text] [Related]  

  • 17. Overlapping technique for hybrid percutaneous coronary intervention strategy utilising drug eluting stent and ABSORB bioresorbable vascular scaffold.
    Yew KL
    Int J Cardiol; 2015 Jan; 178():e8-e10. PubMed ID: 25205484
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioresorbable scaffolds: reflections after a setback - losing a battle does not mean losing the war!
    Colombo A; Azzalini L
    EuroIntervention; 2017 Sep; 13(7):785-786. PubMed ID: 28930075
    [No Abstract]   [Full Text] [Related]  

  • 19. Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?
    Ielasi A; Saino A; Silvestro A; Personeni D; Tespili M
    EuroIntervention; 2014 Jul; 10(3):337. PubMed ID: 24647134
    [No Abstract]   [Full Text] [Related]  

  • 20. Technology limitations of BRS in bifurcations.
    Fox J; Hossainy S; Rapoza R; Serruys PW
    EuroIntervention; 2015; 11 Suppl V():V155-8. PubMed ID: 25983156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.